PR91200

HYDERABAD, India, Aug. 18, 2021 /PRNewswire=KYODO JBN/ --

    Sai Life Sciences, a leading global Contract Research, Development &

Manufacturing Organization [

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility]

(CRO-CDMO), today announced the opening of a new biology facility [

https://www.sailife.com/biology-block/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility]

at its integrated R&D campus in Hyderabad, India. The facility marks an

important milestone in the journey of positioning itself as a differentiated

player in Discovery Biology.

    Making the announcement, CEO & Managing Director of Sai Life Sciences,

Krishna Kanumuri said, "The new facility marks the culmination of a journey we

began two years ago, of creating differentiated value for our discovery clients

through an integrated delivery model across Boston and Hyderabad. By bringing

the best of talent, technology, complementary services and efficiency we are

confident of bringing unique value to our clients and are keen to take on

integrated discovery mandates, at scale."

    Continuing with the company's aggressive growth in its biology services [

https://www.sailife.com/services/discovery/biology/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility],

the new state-of-the-art facility houses expanded in vitro and in vivo biology

services, DMPK, toxicology and a vivarium. The facility augments both, its

capabilities and capacity, to deploy cutting-edge platforms and technologies

for accelerating integrated drug discovery programs.

    Boston-Hyderabad integrated delivery model

    Sai Life Sciences has been steadily growing its biology capabilities to

complement its strong foundation in medicinal chemistry [

https://www.sailife.com/services/discovery/synthetic-medicinal-chemistry/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility],

DMPK [

https://www.sailife.com/services/discovery/dmpk-in-vitro-adme/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility]

and toxicology for supporting its customers across the entire drug discovery

journey from target ID and validation to IND. In 2019, the company opened its

first international R&D facility with a biology lab in Boston, USA. The Boston

Biology Lab [

https://www.sailife.com/boston-usa/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility]

is designed to offer start-up and biotech companies in the region biology

services to address exploratory and custom biology needs.

    The integrated delivery model for Biology aims to provide clients an

optimal solution in terms of expertise, speed, and cost. In this model,

critical exploratory work involving close hand-in-hand collaboration with

clients is done at the Boston lab, following which, established assays are tech

transferred to Hyderabad for greater throughput. A seamless and rapid

technology transfer across sites is achieved through a unified global

organization and matching infrastructure across both sites. Encouraged by the

initial success with the Boston-Hyderabad integrated model, the company plans

to expand its capacity at both locations in the coming months.

    The company's discovery services [

https://www.sailife.com/services/discovery/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility]

support a wide range of global innovator companies from start-ups to large

pharma companies, across a diverse set of therapeutic areas including oncology,

CNS, antivirals, and inflammation among others. With a strong track record of

enduring customer relationships averaging 10+ years, Sai Life Sciences has

advanced 35+ programs to different clinical phases (IND to Phase-III) with the

average turnaround time from Hit/Lead to Candidate being 18 months.

    The new facility culminates the company's journey of unifying its

discovery, early & late phase development and clinical supply capabilities in a

single 13-acre campus housing over 1000 scientists, delivering integrated value

at scale.

   About Sai Life Sciences

   Sai Life Sciences is a full-service CRO-CDMO [

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=biology-facility]

that works with innovator pharma and biotech companies globally, to accelerate

the discovery, development and commercialisation of complex small molecules.

For over two decades, Sai Life Sciences has consistently delivered

high-quality, cost-effective solutions to its diverse customers spanning

biotechs, small, mid and large pharma. Today, it has over 2200 employees across

its facilities in India, UK and USA. https://www.sailife.com

    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

    Photo:

https://mma.prnewswire.com/media/1597144/Sai_Life_Sciences_Biology_Block.jpg

    Source: Sai Life Sciences